Parvovirus B19 is the only member of the Parvoviridae family known to cause disease in humans. Owing to the high level of cell tropism the virus can only replicate in proliferating and differentiating erythroid precursor cells, which are present in human bone marrow and foetal liver. As human bone marrow is very difficult to obtain, an alternative in vitro system for the propagation of B19 virus has been developed, based on the application of mobilized haemapoietic progenitor (apheresis) cells. These cells are routinely harvested from cancer patients after treatment with recombinant human granulocyte/macrophage colony-stimulating factor. Replication of parvovirus B19 in vitro is possible in these cells after stimulation with erythropoietin. Therefore, this system is an easily, accessible alternative to the use of human bone marrow in parvovirus B19 infection assays.
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Human parvovirus B19 is a small, nonenveloped, singlestranded DNA virus that causes a wide variety of human diseases including erythema infectiosum (fifth disease ; Anderson et al., 1983) in children. In adults the infection may be associated with acute or chronic arthritis (Reid et al., 1985 ; Naides et al., 1990) , aplastic crisis in patients with underlying haemolytic disorders (Pattison et al., 1981 ; Young & Ozawa, 1988) , hydrops foetalis in pregnant women (Anderson et al., 1988) , but also with a variety of other conditions. The basis for this great variety of B19-correlated diseases is as yet poorly understood. Most symptoms correlate with the high level of cell tropism of the virus. Cells permissive for virus replication are proliferating and differentiating erythroid precursors in human bone marrow and foetal liver (Ozawa et al., 1986 ; Yaegashi et al., 1989) . Most certainly the target cells are in the erythroid lineage from BFU-E (erythroid burst-forming unit) to erythroblasts (Takahashi et al., 1990) . Therefore, patients with underlying haemolytic anaemia often suffer from severe aplastic crisis after B19 infection and infected foetuses may suffer from severe hydropic changes. Due to the high level of cell tropism, propagation in a continuously growing cell line is not possible.
Since human bone marrow is difficult to obtain, it was necessary to develop a cell culture system as a basis for studies on virus adsorption to the target cells, replication and cell specificity. Apheresis cells are peripheral blood stem cells that are mobilized from bone marrow to peripheral blood in cancer patients through a combined application of chemotherapy and cytokines. They are generally used for autologous stem cell transplantation (He! non, 1993 ; Hawkins & Juttner, 1995) . Apheresis cells are easy to harvest and contain large numbers of permissive progenitor cells for B19 replication compared to normal peripheral blood. We used these cells for infection experiments in vitro and we could show that virus replication is possible. Furthermore, the erythroleukaemic cell line MB-02, which still has the capacity to differentiate into red blood cells (Morgan et al., 1991) , was used in these assays.
Peripheral blood mononuclear cells were obtained by leukapheresis with a continuous flow cell separator (CS 3000 ; Baxter) from patients with solid tumours. These apheresis cells were harvested after treating the patient with recombinant human granulocyte\macrophage colony-stimulating factor (GM-CSF) and conventional chemotherapy. Recombinant human GM-CSF (10 µg\kg body weight) was administered subcutaneously daily for 7 days. Cells were cultivated in longterm culture medium : 75 % Iscove's modified Dulbecco's medium, 12n5 % not inactivated FCS, 12n5 % horse serum, with the addition of human recombinant cytokines IL-1β, IL-3, IL-6 and stem cell factor (SCF) at concentrations of 10 ng\ml, respectively (RjD Systems), hydrocortisone (5i10 −( M; Sigma) and recombinant human erythropoietin (epo, 10 U\ml ; Recormon 1000, Boehringer Mannheim). Cultivation conditions were 37 mC, 5 % CO # and 85 % humidity. Mononuclear cells (MNC ; 2i10() in 300 µl medium were incubated with 25 µl of viraemic patient sera (ca. 10) virus particles\ml) at an m.o.i. of 2n5, according to the following procedure. Cell suspensions and viraemic sera were combined in the wells of 48-well cell culture plates and incubated at 4 mC for 2 h for A. Hemauer and others A. Hemauer and others virus adsorption. Afterwards, cells were incubated at 37 mC for 45 min. Medium was added to a final volume of 2 ml and cells were cultivated as described above. At different time-points post-infection (p.i.) the cells were harvested. Cells were washed three times with PBS and then resuspended in 200 µl RPMI, before storing them and culture supernatants at k20 mC for further use. Cells were lysed through freezing and thawing twice in the presence of 1 % Triton X-100. For examination of the viral DNA, digestion with proteinase K (0n5 mg\ml ; Sigma) and 0n5 % SDS for 4 h at 65 mC was performed in order to destroy the viral capsids. DNA was precipitated with 0n7 vols of cold isopropanol after two extractions with phenol\ chloroform\isoamyl alcohol (25 : 24 : 1 ; USB\Amersham). Purified DNA was digested with BamHI (Boehringer Mannheim) and separated on a 1 % agarose gel together with a digoxigenin (dig)-labelled DNA fragment length marker (Boehringer Mannheim). The gel was subjected to Southern blotting, using dig-labelled probes for DNA detection. A positively charged nylon membrane and all reagents were applied according to the manufacturer's protocols (Boehringer Mannheim). For detecting viral DNA, dig-labelled B19-specific probes were produced by PCR. Probes 1 and 2 cover the regions from nucleotide 2956 to 3448, and 3957 to 4726 in the B19 genome, respectively (nucleotide positions refer to the isolate pYT103, Shade et al., 1986) .
MB-02 cells, a myeloid leukaemic cell line, were cultivated and stimulated as described by Morgan et al. (1991) . After 4 days of stimulation with recombinant human epo infection experiments, cell harvesting and Southern blotting were performed as described above.
Parvovirus B19 exhibits an extraordinary high level of cell tropism ; its replication is restricted to differentiating and proliferating erythroid precursors in human bone marrow or foetal liver. This cell tropism is not exclusively mediated through the cellular receptor globoside (P blood group antigen), which is essential for virus adsorption (Brown et al., , 1994 . The receptor is present on a variety of different cell types and its distribution is not restricted to haemapoietic or erythroid cells and tissues (Rouger et al., 1987) . Propagation in continuously growing cell lines that exhibit erythroid markers is possible in principal, but efficacy of replication is much lower compared to infection of bone marrow cells in vitro (Shimomura et al., 1993 ; Takahashi et al., 1993) . Due to this problem, only few details are known about the replication cycle of parvovirus B19, in contrast to other parvoviruses, which can be easily propagated in vitro. Therefore, we developed an alternative system for parvovirus B19 replication based on mobilized human peripheral blood stem cells. These cells are normally used for haemapoietic reconstitution of tumour patients. Patients are treated with recombinant human GM-CSF, which leads to release of primitive haemapoietic progenitor cells from bone marrow into peripheral blood, where cells can be easily harvested by normal blood donation with a cell separator, a process called leukapheresis (Kanz et al., 1995). As apheresis cells contain large numbers of primitive (CD34 + ) progenitor cells, they should be permissive for parvovirus B19 infection, when stimulated with epo. Therefore, 2i10( MNC, containing about 1 % CD34 + cells, were infected at an m.o.i. of 2n5 using a serum sample derived from a patient in the acute phase of infection and thus containing a high virus concentration (ca. 10) particles\ml). At different time-points after infection (0, 1, 2, 3 days p.i.), cells were harvested and lysed in order to detect replicative intermediates of B19 DNA. These replicative intermediates result from the formation of DNA hairpins at both ends of the genome (no. 1 in Fig. 1 ) which are composed of inverted terminal repeats containing palindromic DNA sequences. The hairpin at the 3h end of the genome functions as a primer for DNA synthesis (no. 1 in Fig.  1 ). As positive and negative strands are packaged in equal amounts in the B19 particles and the B19 genome contains only a single BamHI restriction site, replicative intermediates (nos 3 and 4 in Fig. 1 ) and full length B19 genomes (no. 2 in Fig.  1 ) can easily be distinguished, since BamHI digestion leads to a typical pattern of bands that can be visualized after Southern blotting (see Fig. 1 ; Ozawa et al., 1986) . Purified DNA isolated from infected apheresis cells was digested with BamHI and the fragments were separated on an agarose gel, which was subjected to Southern blotting. In order to detect the B19-specific DNA we used dig-labelled B19-specific DNA probes covering the VP1\VP2 junction region and the C-terminal part of VP1\VP2 in the genome. Directly after the infection (0 days) viral DNA is not detectable in the cell fraction (Fig. 2) . From day 1 to day 3 after infection B19-specific DNA can be detected by Southern blotting. Maximum amounts of DNA are present at day 2 p.i. (Fig. 2) , which is in accordance with GCI B19 infection of apheresis cells B19 infection of apheresis cells data published by Yaegashi et al. (1989) in infection experiments using human foetal liver cells as targets. The pattern of DNA bands shows that active replication occurs in the apheresis cells, as the typical replicative intermediates of 4n0\4n1 kbp and 1n4\1n5 kbp can be detected. The 4n1 kbp and 1n5 kbp fragments show stronger intensities when compared to the 4n0 kbp and 1n4 kbp signal. This is due to the fact that the 4n1 kbp and 1n5 kbp fragments are either generated by digestion of the full genomic B19 DNA (no. 2 in Fig. 1 ) or the replicative intermediates (nos 3 and 4 in Fig. 1 ), in contrast to the 4n0 kbp and 1n4 kbp fragments, which are only created after digestion of replicative intermediates. Full-length genomic DNA of 5n6 kbp can also be visualized on the blot due to incomplete digestion with BamHI. Since no DNA is present directly after the infection procedure (day 0 ; Fig. 2) , it can be concluded that the amount of input B19 DNA used for infection is too low to be detected by Southern blotting. Amplification of the DNA by virus replication is necessary to obtain amounts that can be detected in the assays used. The results clearly show that apheresis cells support the active replication of parvovirus B19 when the cells are stimulated with epo in order to induce erythroid differentiation. Unstimulated apheresis cells could not be infected by B19 virus, which indicates once more the dependence of genome replication on erythroid differentiation (data not shown). Furthermore, apheresis cells show the same pattern and intensity of viral DNA bands after infection as have been shown for infected human bone marrow or foetal liver cells (Ozawa et al., 1986 ; Yaegashi et al., 1989) . This clearly indicates the suitability of apheresis cells for in vitro infection with parvovirus B19, as they are much easier to harvest than human bone marrow or liver from aborted foetuses.
In addition, MB-02 cells, from a human myeloid leukaemic cell line that has been described to go through erythroid differentiation after stimulation with epo, were used for infection experiments. MB-02 cells were grown in the presence of GM-CSF and SCF in order to preserve their myeloid state. When stimulated with epo these cells undergo erythroid differentiation, but cannot be cultivated longer than 8 to 10 days because of apoptotic processes (Morgan et al., 1991) . Infection experiments were performed with MB-02 cells stimulated with epo for 4 days : 2i10( cells were infected at an m.o.i. of 2n5 using the same viraemic patient serum as for infection of the apheresis cells. Purified DNA of infected MB-02 cells did not show any B19 DNA on Southern blots at any time-point after infection. This demonstrates that infection of MB-02 cells was not possible in our experiments. This is in contrast to the data of Munshi et al. (1993) , who described successful infection and DNA replication in this cell line. This may be due to the fact that our serum sample used for infection contains about 10-fold less virus than the one used by Munshi and coworkers, indicating that higher B19 concentrations are necessary for the infection of MB-02. Furthermore, it is probable that another infection protocol is more suitable for MB-02 cells.
The results of our experiments demonstrate that mobilized haemapoietic progenitor cells, harvested from the peripheral blood of cancer patients, contain sufficient amounts of erythroid precursors for the successful propagation of parvovirus B19 after stimulation with epo. Therefore, apheresis cells are an easily, accessible alternative to the use of human bone marrow, which is difficult to obtain in satisfactory quantities. Although apheresis cells are not a continually growing cell line and material is always obtained from different persons, they contain a high number of CD34 + cells, which can easily go through erythroid differentiation. However, we cannot exclude the fact that patient-specific factors may influence the efficacy of B19 replication. Nevertheless, this in vitro system for the infection of parvovirus B19 is an essential tool for the further elucidation of the virus replication cycle and its almost unknown cell tropism. As a result, this will also lead to a better understanding of the course of infection and B19 pathogenesis.
